TELO insider transaction filings
Telomir Pharmaceuticals, Inc. — 17 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-27. Screen TELO transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 3 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Del Giudice Matthew Paul — Director | 1 | — | — | 1 |
| MacPherson Edward Clouston — Director | 1 | — | — | 1 |
| Whalen Matthew Pratt — Director | 1 | — | — | 1 |
Recent Form 4 filings — Telomir Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-27 | 4 | Del Giudice Matthew Paul — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | MacPherson Edward Clouston — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Whalen Matthew Pratt — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Aminov Erez — CEO and Chairman, Director | Grant/award (A): 1,960,170 (derivative) · Disposition to issuer (D): 1,960,170 (derivative) · Grant/award (A): 2,000,000 (derivative) · Disposition to issuer (D): 2,000,000 (derivative) | EDGAR |
| 2026-05-22 | 4 | Whalen Matthew Pratt — Director | Grant/award (A): 25,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2026-05-22 | 4 | MacPherson Edward Clouston — Director | Grant/award (A): 25,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2026-05-22 | 4 | Del Giudice Matthew Paul — Director | Grant/award (A): 25,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2026-04-24 | 4 | Aminov Erez — CEO and Chairman, Director | Other (J): 7,319,710 @ $1.37 | EDGAR |
| 2025-05-30 | 4 | Aminov Erez — CEO and Chairman, Director | Grant/award (A): 2,000,000 (derivative) @ $0 · Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Bay Shore Trust — 10% owner | Gift (G): 100,000 (derivative) | EDGAR |
| 2024-09-04 | 4 | Yanez Michelle — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | Jerman Michael Allen — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | MacPherson Edward Clouston — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | Aminov Erez — CEO & Chairman, Director | Grant/award (A): 1,960,170 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | Del Giudice Matthew Paul — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | Whalen Matthew Pratt — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Bay Shore Trust — 10% owner McNulty Brian Patrick — 10% owner | Purchase (P): 49,000 @ $7 · Purchase (P): 40,000 @ $7 · Purchase (P): 49,000 @ $7 | EDGAR |
Recent 8-K events — Telomir Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-17 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TELO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →